Back to top
more

MediWound (MDWD)

(Delayed Data from NSDQ)

$18.24 USD

18.24
73,119

+0.58 (3.28%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $18.16 -0.08 (-0.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?

by Zacks Equity Research

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for MediWound (MDWD) points to a 76.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'

by Zacks Equity Research

MediWound (MDWD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 17.39% and 0.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?

by Zacks Equity Research

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -15.63% and 7.58%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 134.8% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

MediWound (MDWD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 171.8% in MediWound (MDWD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 124.39% and 14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Perspective Therapeutics (CATX) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 4.40% and 21.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 6.82% and 0.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -41.94% and 28.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -2.02% and 3.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of -7.69% and 40.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of 107.41% and 24.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?